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In Boston in 1954, Hartwell Harrison, the chief of urology at 
Harvard University, harvested a kidney and performed the first 
ever human organ transplantation [1]. The concept of cell trans-
plantation developed after kidney transplantation and led to the 
first human bone marrow cell transplantation in the 1970s. At 
that time, researchers combined the scientific fields of device 
and material sciences with cell biology and in effect pioneered a 
new field called “tissue engineering” [2]. The first use of the term 
“tissue engineering” can be traced in the literature to a reference 
dealing with corneal tissue in 1985 [3]. The discovery of mouse 
embryonic stem (ES) cells in the early 1980s gave a huge boost 
to the stem cell field and led to the description of human ES 
(hES) in 1998 [4]. The creation of the first cloned mammal, a 
sheep named Dolly, was announced in 1997 [5]. Two years lat-
er, the term “regenerative medicine” was coined to describe the 
unifying goal of cell transplantation, tissue engineering, and 
nuclear transfer, i.e., the regeneration of living tissues and or-
gans [6]. Over the past decade, the number of patients waiting 
for transplantation has doubled, while the actual number of 
transplantations has remained practically unchanged. This dis-
parity is a consequence of our aging population. As time passes, 
we get older and older, and medicine does a better job of keep-
ing us alive. However, as we age, our organs tend to fail more of-
ten. This, then, is our new challenge. Although advanced medi-
cines and treatments have saved many lives, we now face a ma-
jor shortage of organs. The human body has many organs, each 
of which has a cell population that is ready to take over at the 
time of injury. It happens every day of our lives. Thus, our body 
is constantly regenerating. When challenges occur through an 
injury or a disease, the human body’s first reaction is to seal off 
the area. Whether it is the organs inside the body or the skin, 
the development of scar tissue is the immediate response to 
solve the problem. How can we harness that power? One way is 
through the use of smart biomaterials. In 1996, the first use of 
natural biomaterials in humans for tissue regeneration demon-
strated that smart biomaterials could be used as a bridge in the 
treatment of an injured urethra [7]. First, the injured area was 
closed off from the outside environment. Then, cells that were 
regenerated in the body crossed the bridge and followed the 
pathway or channel that connected to the bladder or to outside 
the body. Tissue engineering for urethral reconstruction may 
involve matrices alone, wherein the body’s natural ability to re-
generate is used to orientate or direct new tissue growth, or the 
use of matrices with cells. Acellular collagen matrices that are 
derived from donor bladder submucosa have been used both 
experimentally and clinically for urethral replacement. Urethra 
successfully regenerates, but only over a limited distance. What 
if the injury is in a larger organ? What can we do to repair inju-
ries in structures that are much larger than the limited distance 
of regeneration? Researchers have turned to cells to solve these 
problems. The strategy is to take a very small piece of tissue from 
the injured or diseased organ and to tease that tissue apart into 
its basic components. Then, the patient’s own cells are taken and 
grown outside the body in large quantities. Next, scaffold mate-
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rials are used. The scaffold acts as a cell delivery vehicle, bringing 
the cells into the body and allowing them to regenerate into new 
tissue. Scaffold materials are designed to disintegrate in the body 
a few months later. Currently, gastrointestinal (GI) segments are 
commonly being used as tissue for bladder and urethral replace-
ment or repair. However, GI tissue is designed to absorb specific 
solutes, whereas bladder and urethral tissue are designed for the 
excretion of solutes. When GI tissue comes in contact with the 
urinary tract, multiple complications may occur, such as infec-
tion, metabolic disturbances, urolithiasis, perforation, increased 
mucus production, and malignancy [8]. James J. Yoo, the Asso-
ciate Director of the Wake Forest Institute for Regenerative Med-
icine, focuses his work on growing and regenerating tissues and 
organs. His team engineered the first lab-grown organ to be 
implanted into a human - a bladder. His article ‘in this issue of 
the Journal’ [9] will introduce the novel tissue engineering-based 
regenerative strategies that are being applied to bladder recon-
struction and will discuss how these strategies can be used to 
treat the neurogenic bladder.
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